Filing Flows › AIM ImmunoTech (AIM) › Q3 2025
AIM ImmunoTech (AIM) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 17, 2025
AIM ImmunoTech (AIM) reported revenue of $26K for the third quarter 2025 (Q3 2025), -26% from a year earlier and +4% from the quarter before.
AIM ImmunoTech, Q3 2025: revenue $26K (-26% year over year), net loss $3.3M, operating cash flow −$5.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26K | +4% | -26% |
| Operating profit | −$2.4M | — | — |
| Net earnings | −$3.3M | — | — |
| Operating cash flow | −$5.1M | — | — |
What changed
Revenue was $26K in Q3 2025, down 26% year over year and up 4% from the previous quarter.
Operating costs exceeded revenue by $2.4M, an operating margin of -9411.5%. Total costs fell 45% while revenue fell 26%. The quarter ended with a net loss of $3.3M, wider than the previous quarter's $2.8M loss.
Operating cash flow was −$5.1M. Non-cash charges added back $54K of depreciation and amortization. Working capital and other items used $1.8M.
Questions
What was AIM ImmunoTech's revenue in the third quarter 2025?
AIM ImmunoTech (AIM) reported revenue of $26K for the third quarter 2025 (Q3 2025), -26% from a year earlier and +4% from the quarter before.
Source: AIM ImmunoTech 10-Q on SEC EDGAR.